Cognition Therapeutics 配当と自社株買い

配当金基準チェック /06

Cognition Therapeutics配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-34.8%

バイバック利回り

総株主利回り	-34.8%
将来の配当利回り	n/a
配当成長	n/a
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
配当性向	n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

分析記事 • Mar 28

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

新しいナラティブ • Mar 26

DLB Psychosis Program And Biomarker Strategy Will Shape Long Term Upside Potential

Catalysts About Cognition Therapeutics Cognition Therapeutics is a clinical stage biopharmaceutical company focused on developing zervimesine for neurodegenerative diseases such as dementia with Lewy bodies and Alzheimer's disease. What are the underlying business or industry changes driving this perspective?

分析記事 • Nov 12

We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, Cognition...

分析記事 • Jul 04

We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

分析記事 • Dec 20

Cognition Therapeutics (NASDAQ:CGTX) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

分析記事 • Sep 06

Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Jul 31

Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease

Summary Cognition Therapeutics' stock dropped over 40% after Phase 2 trial results for Alzheimer's disease. Results showed cognitive benefit but fading statistical significance over time. CT1812 did not outperform placebo on all rating scales over 3-6 months, raising concerns for future milestones and larger trials. Financial reliance on NIH grants poses risks, and ongoing trials in dementia with Lewy Bodies, Alzheimer's and dry AMD have the potential for further stock decline. Read the full article on Seeking Alpha

分析記事 • May 22

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Seeking Alpha • Apr 18

Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's

Summary Cognition Therapeutics is set to report topline data from its Phase 2 trial in Alzheimer's disease in mid-2024. CT1812, the company's lead drug candidate, is a sigma-2 receptor antagonist for Alzheimer's and aims to prevent the binding of toxic Aβ oligomers. Preliminary data from the ongoing SHINE trial showed some interesting results, but were not consistent with other previous studies, raising caution about the upcoming data. At a ~$70 million market cap with about half of that cash, the topline readout could be a binary event for the stock. Read the full article on Seeking Alpha

分析記事 • Nov 30

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

分析記事 • Aug 15

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

分析記事 • Mar 17

Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Sep 27

Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study

Cognition Therapeutics (NASDAQ:CGTX) said it received a $2.14M grant from the National Institute on Aging (NIA) to help complete an ongoing study of CT1812 in adults with mild-to-moderate Alzheimer's disease. The study called SEQUEL will evaluate if CT1812 results in a normalization of the EEG patterns. The trial is enrolling 16 adults who will receive either CT1812 or placebo, the company said in a Sept. 27 press release. Cognition noted that the study is taking place at the Amsterdam UMC Dept. of Neurology/Alzheimer Center and Brain Research Center. The NIA, a division of the National Institutes of Health (NIH), awarded a $3.2M grant in 2020 to support the study and has now awarded $2.14M, the company added. CGTX +12.28% to $1.92 premarket Sept. 27

分析記事 • Aug 12

We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Aug 05

Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar

An analysis of biomarker data from Cognition Therapeutics' (NASDAQ:CGTX) Alzheimer's disease candidate CT1812 indicate the oral once-daily treatment supports a synaptoprotective mechanism of action and has a role in normalizing cellular processes. Proteomic analyses demonstrated CT1812's impact on several Alzheimer's biomarkers, including YKL-40, which is an indicator of inflammation and is upregulated in the disease. Results showed that participants given CT-1812 saw declining levels of YKL-40. The candidate also had a significant impact on cerebrospinal fluid levels of clusterin, a genetic risk factor for Alzheimer's. Cognition closed up 62% on Thursday but is down 16% in Friday premarket trading.

分析記事 • Mar 19

We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

決済の安定と成長

配当データの取得

安定した配当: CGTXの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: CGTXの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Cognition Therapeutics 配当利回り対市場

CGTX 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (CGTX)	n/a
市場下位25% (US)	1.4%
市場トップ25% (US)	4.2%
業界平均 (Pharmaceuticals)	2.1%
アナリスト予想 (CGTX) (最長3年)	n/a

注目すべき配当: CGTXは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: CGTXは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: CGTXの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: CGTXが配当金を報告していないため、配当金の持続可能性を計算できません。

高配当企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/05/24 10:35
終値	2026/05/22 00:00
収益	2026/03/31
年間収益	2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Cognition Therapeutics, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。7

アナリスト	機関
Mayank Mamtani	B. Riley Securities, Inc.
null null	B. Riley Securities, Inc.
William Wood	B. Riley Securities, Inc.

Cognition Therapeutics 配当と自社株買い

配当金 基準チェック /06

主要情報

最近の配当と自社株買いの更新

Recent updates

Cognition Therapeutics, Inc. Completes Meeting With FDA For Zervimesine (CT1812) In Dementia With Lewy Bodies With Psychosis

New minor risk - Market cap size

Cognition Therapeutics, Inc., Annual General Meeting, Jun 17, 2026

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

New major risk - Financial position

DLB Psychosis Program And Biomarker Strategy Will Shape Long Term Upside Potential

Cognition Therapeutics, Inc. to Report Q4, 2025 Results on Mar 26, 2026

Cognition Therapeutics Presents Evidence Of Zervimesine’s Impact On Neuropsychiatric Symptoms Of Dementia With Lewy Bodies

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (Ct1812) in Dementia with Lewy Bodies

New minor risk - Market cap size

Cognition Therapeutics, Inc. Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics, Inc. Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease Conference

Price target increased by 7.7% to US$3.50

Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (Ct1812) in Early Alzheimer's Disease

We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

New major risk - Financial position

Cognition Therapeutics, Inc. Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target

Cognition Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $30.135 million.

Cognition Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $30.135 million.

Cognition Therapeutics, Inc. Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease

Cognition Therapeutics, Inc. Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease

Cognition Therapeutics, Inc. Announces Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) to Be Presented in A Podium Presentation at AAIC

Cognition Therapeutics Completes End-Of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease

We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

New major risk - Share price stability

Cognition Therapeutics, Inc. Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB)

Cognition Therapeutics, Inc. Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy

Insufficient new directors

Cognition Therapeutics, Inc., Annual General Meeting, Jun 18, 2025

Cognition Therapeutics, Inc. Presents Results At AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes

New major risk - Shareholder dilution

Price target decreased by 11% to US$5.60

Insufficient new directors

Cognition Therapeutics, Inc. to Report Q4, 2024 Results on Mar 20, 2025

Cognition Therapeutics Successfully Passes Pre-Defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy

Cognition Therapeutics, Inc. Announces Positive Phase 2 'Shimmer' Study of Zervimesine (Ct1812) in Dementia with Lewy Bodies (Dlb) Will Be Presentation At Ilbdc

Cognition Therapeutics (NASDAQ:CGTX) Will Have To Spend Its Cash Wisely

Cognition Therapeutics, Inc. Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

Cognition Therapeutics Announces All Participants Completes Their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

Cognition Therapeutics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?

Cognition Therapeutics, Inc. Publishes EEG Findings from Phase 2QUEL Study of CT1812 in Mild-to-Mod Moderate Alzheimer's Disease

Cognition Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease

Cognition Therapeutics, Inc’s Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients

Cognition Therapeutics, Inc. Announces Results from Cognition Therapeutics' Phase 2 Shine Study of CT1812 in Mild-To-Moderate Alzheimer's Disease Accepted for Presentation at AAIC

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

New major risk - Financial position

Cognition Therapeutics, Inc. Completes Enrollment in Phase 2 SHIMmer Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

Cognition Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's

Cognition Therapeutics, Inc. to Report Q4, 2023 Results on Mar 26, 2024

Cognition Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $11.499999 million.

Cognition Therapeutics, Inc. Presents Analyses at AD/PD 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-To-Mod Moderate Alzheimer's Disease

Cognition Therapeutics, Inc. Appoints Quang Pham as Board Director

Cognition Therapeutics, Inc. and Collaborators At Yale and ACTC Announce Oral Late-Breaking Presentation on the Start Study in Early Alzheimer’s Disease At CTAD

Cognition Therapeutics, Inc. Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease At CTAD

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

Price target decreased by 19% to US$6.25

Cognition Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Share price stability

Cognition Therapeutics, Inc. and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 Start Study in Early Alzheimer's Disease

Cognition Therapeutics, Inc. Announces Positive Topline Results for CT1812 Phase 2 Sequel Study for Mild-To-Moderate Alzheimer’s Disease

Cognition Therapeutics, Inc. Publishes Clinical Evidence that CT1812 Displaces Aß Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease

Price target decreased by 26% to US$7.75

Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans

Price target decreased by 8.7% to US$10.50

Cognition Therapeutics, Inc. Completes Enrollment of CT1812 Phase 2 Sequel Study for Mild-to-Moderate Alzheimer’s Disease

Cognition Therapeutics, Inc. Announces New “Conversations” Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer’s Disease

配当金基準チェック /06